• Maha Fayez Albogami, Muneer S AlJomaie, Saad Saleh Almarri, Sultan Al-Malki, Shadi Tamur, Maryam Aljaid, Abdullah Khayat, and Ahmad Alzahrani.
• College of Medicine, Taif University, Taif, Saudi Arabia.
• Patient Prefer Adher. 2023 Jan 1; 17: 276127722761-2772.

BackgroundAnxiety about using topical corticosteroids (TCS) for childrens among parents and caretakers is a common cause of treatment failure and an overall decline in the child's quality of life. The purpose of this study was to examine the perspectives and worries of parents of Atopic dermatitis (AD) children regarding TCS. Additionally, we investigate the degree of phobia in relation to the use of the TCS.Materials And MethodsA convenience sample of 301 parents of children who had been identified with atopic dermatitis from two hospitals in Taif city were enrolled in this study. Parents who chose to participate were sent a questionnaire measuring their level of fear of TCS using the TOPICOP© scale, which also included inquiries about their demographics and clinical characteristics. Multivariate analysis was used to determine what factors influence people's overall levels of fear.ResultsThe median global TOPICOP score was 66.6% (IQR 60.4-75%), SD 12.83%, which showed that nearly two-thirds of the participants showed corticosteroid phobia. A multifactorial ANOVA model showed that parents who had a female child with AD and mothers who had experienced drug allergies had a significant influence on TOPICOP scores (P<0.05).ConclusionTopical corticosteroid phobia is widespread among parents of children patients with AD in Taif. Regarding the utilization of TCS, we place a strong emphasis on the significant role that physicians play as sources of reliable information and proper education.© 2023 Albogami et al.

4 keywords...

hide…